QC
COGT icon

Quadrature Capital’s Cogent Biosciences COGT Stock Holding History

Quadrature Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,475
Closed -$581K – 1313
2025
Q3 		$581K Buy
+40,475
New +$480K 0.01% 486

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Quadrature Capital's COGT Position: Q4 2025 in Review

Quadrature Capital sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 40,475 shares — an estimated $581K sold.

Quadrature Capital first reported a position in COGT in Q3 2025 and held it in 1 quarter. The position peaked at $581K in Q3 2025. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

  • Quadrature Capital reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 40,475 Cogent Biosciences shares in Q4 2025, an estimated $581K.
  • Quadrature Capital first reported a position in Cogent Biosciences in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's Cogent Biosciences position peaked at $581K in Q3 2025.
  • 267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.